Literature DB >> 27192669

Essential Medicines in the United States--Why Access Is Diminishing.

Jonathan D Alpern1, John Song1, William M Stauffer1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27192669     DOI： 10.1056/NEJMp1601559

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

1.  Clinical Reasoning: A 48-year-old woman with confusion, personality change, and multiple enhancing brain lesions.

Authors:  James M Hillis; Alex B Ruan; Jacob E Lazarus; Mary W Montgomery; Aaron L Berkowitz
Journal:  Neurology       Date:  2018-05-08       Impact factor: 9.910

2.  Generic Drugs in the United States: Policies to Address Pricing and Competition.

Authors:  Ravi Gupta; Nilay D Shah; Joseph S Ross
Journal:  Clin Pharmacol Ther       Date:  2019-01-10       Impact factor: 6.875

3.  Costs and Prescribing Patterns of Anthelmintics in the United States Military: A Retrospective Analysis.

Authors:  Alyssa R Lindrose; Jamie A Fraser; Patrick W Hickey; Edward Mitre
Journal:  Open Forum Infect Dis       Date:  2022-02-14       Impact factor: 3.835

Review 4.  Essential medicines for universal health coverage.

Authors:  Veronika J Wirtz; Hans V Hogerzeil; Andrew L Gray; Maryam Bigdeli; Cornelis P de Joncheere; Margaret A Ewen; Martha Gyansa-Lutterodt; Sun Jing; Vera L Luiza; Regina M Mbindyo; Helene Möller; Corrina Moucheraud; Bernard Pécoul; Lembit Rägo; Arash Rashidian; Dennis Ross-Degnan; Peter N Stephens; Yot Teerawattananon; Ellen F M 't Hoen; Anita K Wagner; Prashant Yadav; Michael R Reich
Journal:  Lancet       Date:  2016-11-08       Impact factor: 79.321

5.  Trends in Pricing and Generic Competition Within the Oral Antibiotic Drug Market in the United States.

Authors:  Jonathan D Alpern; Lei Zhang; William M Stauffer; Aaron S Kesselheim
Journal:  Clin Infect Dis       Date:  2017-11-13       Impact factor: 9.079

Review 6.  Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.

Authors:  Toon van der Gronde; Carin A Uyl-de Groot; Toine Pieters
Journal:  PLoS One       Date:  2017-08-16       Impact factor: 3.240

7.  Access to benznidazole for Chagas disease in the United States-Cautious optimism?

Authors:  Jonathan D Alpern; Rogelio Lopez-Velez; William M Stauffer
Journal:  PLoS Negl Trop Dis       Date:  2017-09-14

8.  A systematic synthesis of direct costs to treat and manage tuberculosis disease applied to California, 2015.

Authors:  Peter Oh; Lisa Pascopella; Pennan M Barry; Jennifer M Flood
Journal:  BMC Res Notes       Date:  2017-08-30

9.  Is greater generic competition also linked to lower drug prices in South Korea?

Authors:  Kyung-Bok Son
Journal:  Health Econ Rev       Date:  2020-09-15

10.  Glaucoma Medication Preferences among Glaucoma Specialists in Mexico.

Authors:  Gabriel Lazcano-Gomez; Daniela Alvarez-Ascencio; Cindy Haro-Zuno; Mauricio Turati-Acosta; Magdalena Garcia-Huerta; Jesus Jimenez-Arroyo; Rafael Castañeda-Diez; Armando Castillejos-Chevez; Roberto Gonzalez-Salinas; Francisca Dominguez-Dueñas; Jesus Jimenez-Roman
Journal:  J Curr Glaucoma Pract       Date:  2017-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.